Usefulness of F-18 FDG PET/CT in Assessment of Recurrence of Cervical Cancer After Treatment

Lee, Minkyung; Lee, Yukyung; Hwang, Kyung Hoon; Choe, Wonsick; Park, Chan Yong

doi:10.1007/s13139-010-0059-3

Cited by 16 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to now, the clinical use of FDG PET/CT has been established in gynecological malignancies such as cervical, ovarian, and vulvar cancer. However, only a few studies [20,21] have reported the prognostic value of FDG PET/CT in gynecological malignancies. To the best of our knowledge, this is the second report regarding the prognostic value of FDG PET/CT by semiquantitatively measuring the SUVmax of primary tumors and LNs in endometrial cancer.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer

Kim

Choi

Jeong

et al. 2013

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose We evaluated the potential prognostic value of 18 Ffluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) in patients with stage IIIC/ IV endometrial cancer. Methods Patients with stage IIIC/IV endometrial cancer who had undergone FDG PET/CT workup for staging were enrolled. Maximum standardized uptake values (SUVmax) measured from regions of interest (ROIs) of the primary tumor (SUVt) and lymph nodes (SUVn) were correlated with overall survival (OS). The SUVn was defined as the highest SUVmax of the metastatic lymph nodes. Survival probability was assessed using the Kaplan-Meier method. Results A total of 42 patients with a median age of 55.5 years (range 32-76 years) were included. Twenty-nine percent (n =12) of patients were premenopausal and 71 % (n =30) were postmenopausal. The average SUVt was 12.9 (range 1.8-36.5), and the average SUVn was 7.3 (range 2.0-22.5). Median follow-up time was 25.9 months (range 1-84 months). Using a SUVt of 9.5 as a cutoff value, two groups with different rates were determined (P =0.026). In addition, patients with a low SUVn had significantly better OS than those with a high SUVn (P =0.003). Patients in the International Federation of Obstetrics and Gynecology (FIGO) stage IV group with SUVt≥9.5 or SUVn≥7.3 showed a significantly longer OS than the other groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer

Kim

Choi

Jeong

et al. 2013

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Lee et al studied 51 patients with treated cervical cancer and found tumor recurrence or metastasis in 37. They found PET/CT to have a sensitivity of 97.3%, a specificity of 71.4%, and an accuracy of 90.2%[39]. PET/CT has been shown to detect metastases in asymptomatic patients and in patients with increasing tumor markers.…”

Section: Follow-up Evaluationmentioning

confidence: 99%

[18F]-2-Fluoro-2-Deoxy-D-glucose–PET Assessment of Cervical Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Does PET/CT improve the accuracy of diagnosis of recurrence compared to CT or MRI in cervical cancer? Statistical analysis for the diagnostic accuracy of CT, MRI, and PET/CT has not been performed due to heterogeneity of the statistical analysis from each studie [ 68 69 70 71 ]. From the review of each study, PET/CT could be used to identify the recurrence of cervical cancer when recurrence is not identified or recurrence is suspicious with conventional image.…”

Section: Clinical Considerations and Recommendationsmentioning

confidence: 99%

Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

et al. 2017

View full text Add to dashboard Cite

Clinical practice guidelines for gynecologic cancers have been developed by academic society from several countries. Each guideline reflected their own insurance system and unique medical environment, based on the published evidence. The Korean Society of Gynecologic Oncology (KSGO) published the first edition of practice guidelines for gynecologic cancer treatment in late 2006; the second edition was released in July 2010 as an evidence-based recommendation. The Guidelines Revision Committee was established in 2015 and decided to develop the third edition of the guidelines in an advanced format based on evidence-based medicine, embracing up-to-date clinical trials and qualified Korean data. These guidelines cover strategies for diagnosis and treatment of primary and recurrent cervical cancer. The committee members and many gynecologic oncologists derived key questions through discussions, and a number of relevant scientific literature were reviewed in advance. Recommendations for each specific question were developed by the consensus conference, and they are summarized here, along with the details. The objective of these practice guidelines is to establish standard policies on issues in clinical practice related to the management in cervical cancer based on the results in published papers to date and the consensus of experts as a KSGO Consensus Statement.

show abstract

Usefulness of F-18 FDG PET/CT in Assessment of Recurrence of Cervical Cancer After Treatment

Cited by 16 publications

References 24 publications

Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer

Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer

[18F]-2-Fluoro-2-Deoxy-D-glucose–PET Assessment of Cervical Cancer

Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

Contact Info

Product

Resources

About